NEW YORK (GenomeWeb News) — Synthetic protein drug developer ProMetic Biosciences will develop a synthetic ligand affinity for Novartis, the company said today.
 
PBL, a subsidiary of ProMetic Life Sciences, said Novartis Vaccines has hired it to screen chemical libraries for ligands that may be used to purify a new vaccine product Novartis currently has in clinical trials.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.